A preclinical biotech raise starts with a clear question: what will the next financing prove, and which investor is equipped to help prove it? Some firms build a company around a discovery. Others back an existing team with a defined programme and evidence package. The difference changes whom to approach and what to send.
This guide compares 15 investors with documented company-creation or early scientific-investment routes relevant before human trials. It helps founders separate scientific fit, evidence readiness, geography and the working relationship. It is not a ranking by assets or a list of biotech stocks.
Match the investor to the next evidence milestone
Preclinical is not one uniform level of readiness. A discovery that needs a company, an existing programme with experimental evidence and an established team preparing its next development step can all sit before human trials. They do not necessarily belong in the same investor process.
Curie.Bio's founder guide distinguishes a Seed Fund focused on preclinical milestones from a Breakout Fund focused on clinical activity. Biovance requires appropriate preclinical models and patented or patentable assets. Third Rock describes seed validation before a company launches. Those differences are more useful than a generic early-stage label.
Three routes to compare
- Company creation: Bring the discovery, scientific team and a clear account of what still needs to be built. Ask how leadership and development responsibilities are shared.
- Financing an existing company: Show its present evidence, team, asset position and the next milestone. Establish what is funded already and what this round adds.
- A later development round: If the financing is intended to support clinical milestones, ask whether the investor's separate later-stage strategy is the relevant route.
The broader biotech and life-sciences investor guide covers a wider range of businesses and stages. This page narrows the decision to preclinical scientific readiness and the company-building model.
Compare 15 preclinical biotech investor routes
The table describes published entry points, not guaranteed availability. Company-building firms may originate projects selectively rather than accept ordinary outside-company rounds. Where a firm does not publish a precise geographic rule, confirm it directly instead of inferring eligibility from an office.
| Investor | Product focus | Stage or route | Geographic filter |
|---|---|---|---|
| Atlas Venture | Therapeutic biotechnology, platforms and products | Seed-led company creation with scientific founders and EIRs | Innovation sourced worldwide; confirm company and operating-location fit |
| Third Rock Ventures | Therapeutics built from scientific discovery | Seed validation before company launch, then active company building | Confirm project and company-location fit with the team |
| Versant Ventures | Novel biotechnology with academic founders | Discovery-engine company formation and venture investment | Discovery engines in the US and Europe; confirm eligibility for each route |
| Curie.Bio | Therapeutic programmes across modalities and therapeutic areas | Seed Fund toward preclinical milestones; separate Breakout clinical strategy | Published guide accepts ideas across geographies; confirm operating arrangements |
| AdBio Partners | Early life-science innovation and academic spinouts | Initial financing, co-founding and early venture development | Published early-stage European focus; confirm any Canadian or other mandate |
| Scion Life Sciences | Medicines addressing clinically important problems | Speculative incubation through company formation and later financing | Source of innovation is flexible; confirm company geography |
| 5AM Ventures | Therapeutics and life-science company formation | 4:59 discovery/incubation before Series A; separate core venture strategy | Confirm company eligibility with the relevant investment team |
| MPM BioImpact | Drug-development companies and scientific company creation | Company formation and early venture; public strategies are separate | Confirm geography and strategy with the investment team |
| Forbion | Private medicine development and biopharmaceutical company building | Discovery onward; seed via BGV relationship, Ventures for company building | Confirm geography and eligibility for the specific strategy |
| Sofinnova Partners | Biopharma and medtech with strong intellectual property | Early healthcare investment and company creation | Capital strategy: Europe |
| ARCH Venture Partners | Science-led companies, including biotechnology | Formation-stage company building with flexible investment sizes | Global company-building positioning; confirm specific domicile requirements |
| Frazier Life Sciences | Innovative biopharmaceuticals | Seed and company creation through later development; public investing separate | Published global investing; confirm company-creation arrangements |
| Biovance Capital | Therapeutics across modalities and therapeutic areas | Seed and Series A; requires appropriate preclinical models and patentable assets | Europe, with a Southern European focus |
| Mission BioCapital | Early life sciences | First experiments and company formation through clinical development | Confirm company geography and any shared-lab arrangements |
| Epidarex Capital | Life sciences, including biotechnology and pharmaceuticals | Founding, seed or Series A investment in research spinouts | US and UK research hubs |
Read provider criteria and approach routes
1. Atlas Venture
Atlas is a company-building conversation, not simply a place to send a completed financing deck. Its seed-led model brings scientific founders and entrepreneurs-in-residence together around new medicines. Explain the scientific opportunity, what exists today and which operating capabilities a new company needs. Worldwide sourcing is not a published promise to finance every domicile.
Founder route: Published general contact. Official criteria.
2. Third Rock Ventures
Third Rock describes an extended seed period in which it validates mechanisms and matures a programme before launch. Its people can then take interim leadership roles. A founder should frame the opportunity as a potential company build and discuss how responsibilities would be shared. Do not assume that an ordinary outside-company seed round uses the same process.
Founder route: Official contact details on the approach page. Official criteria.
3. Versant Ventures
Versant's in-house discovery engines partner with academic founders to launch biotech companies. Inception in San Diego and Ridgeline in Basel make the company-creation route concrete. Present the discovery, its evidence and the capabilities required to develop it. An engine's location is not a blanket investment restriction or an open application programme.
Founder route: Official office and discovery-engine contacts. Official criteria.
4. Curie.Bio
Curie.Bio's Seed Fund explicitly supports progress toward preclinical proof of concept or a development candidate. It considers ideas, existing companies and biopharma spinouts. The guide combines investment with scientific and operational support, so evaluate the working model as well as capital. Its Breakout Fund targets a different, clinical-milestone job; do not treat the two as interchangeable.
Founder route: Idea or company contact form. Official criteria.
5. AdBio Partners
AdBio, formerly Advent France Biotechnology, works with research institutions and technology-transfer offices and can co-found companies with scientific founders. Its team may provide initial funding and interim operating support. A university spinout should explain the translation from research to a company. The Montreal office does not, by itself, establish an unrestricted Canadian investment mandate.
Founder route: Official general contact. Official criteria.
6. Scion Life Sciences
Scion builds around experiments that test the main risks before committing to a company. Its stated investment pillars include established modalities, well-understood biology and the ability to stand alone. The contact page invites lab projects and assets available for licensing. An exciting mechanism outside those pillars needs a specific fit discussion, not a generic biotech pitch.
Founder route: Public form for lab projects and licensable assets. Official criteria.
7. 5AM Ventures
Use the 4:59 initiative when the job is discovering, incubating and funding science toward proof-of-concept data before a Series A. The core venture strategy emphasizes early private therapeutics, particularly Series A. The public-equity and later-private Opportunities strategy serves another stage. These are routes within one investor, not three extra names for a shortlist.
Founder route: Official contact; identify the 4:59 or venture route. Official criteria.
8. MPM BioImpact
MPM BioImpact combines investing with a company-creation model supported by entrepreneur partners. That makes the conversation relevant before clinical development when the opportunity needs a company and operating team, not only financing. Specify whether you are proposing a new build or an investment in an existing business. Its public-market activities are not evidence of preclinical eligibility for every fund.
Founder route: Published general contact on the official site. Official criteria.
9. Forbion
Forbion separates seed funding through its BGV joint venture, company building through Ventures and expansion through Growth. Its Human Health disclosures include discovery-stage private medicine companies. An early founder should identify the appropriate route before approaching the team. This guide counts the connected routes once and does not present Growth as an idea-stage fund.
Founder route: Official contact; specify the early-stage strategy. Official criteria · Supporting official evidence.
10. Sofinnova Partners
Sofinnova Partners' Capital strategy explicitly combines early-stage healthcare investment and company creation in Europe. For a preclinical therapeutic company, connect the scientific case with defensible intellectual property and the next development milestone. This is the European firm, not Sofinnova Investments in the US. Other Sofinnova strategies do not automatically share the same entry point.
Founder route: Submit a project link on the official site. Official criteria.
11. ARCH Venture Partners
ARCH describes supporting science companies from formation and adjusting investment to what a company needs. A founder can assess it for opportunities that require scientific company building before a conventional clinical story exists. Explain the discovery and the business being created. Do not turn its historical range of investments into a promised cheque size for your round.
Founder route: Official contact details; no open pitch form verified. Official criteria.
12. Frazier Life Sciences
Frazier's company-creation activity is current, including its 2026 appointment dedicated to forming therapeutics companies. That is a different conversation from purchasing public biotech shares. Identify the scientific programme, the company that could be formed around it and the team gaps. Use the relevant investment or company-creation team rather than a media or limited-partner inbox.
Founder route: Official company-creation and investment team; no open pitch form verified. Official criteria · Supporting official evidence.
13. Biovance Capital
Biovance makes its evidence threshold unusually clear: appropriate preclinical models and patented or patentable assets. A concept without that foundation is not equivalent to a ready seed proposal. Its early-stage European focus can fit a company before human trials, but the founders still need to explain the data and ownership position rather than rely on the preclinical label.
Founder route: Official contact page. Official criteria.
14. Mission BioCapital
Mission BioCapital connects early investment with a network of shared labs and operating support, describing support from first experiments toward the clinic. That makes practical infrastructure needs part of the fit conversation. The site still displays a 2024 Platinum programme announcement; this guide does not present that old call as an open 2026 opportunity.
Founder route: Published contact, shared-lab network, events or portfolio introductions. Official criteria.
15. Epidarex Capital
Epidarex explicitly funds university and research-institution spinouts in US and UK hubs. It lists scientific differentiation, intellectual property, capital efficiency and development strategy among its criteria. A founder should show how research becomes a focused company and what the first financing establishes. Its published submission route is useful without implying that every plan receives a meeting.
Founder route: Business-plan submission instructions and published inbox. Official criteria.
Build an investor brief around evidence, not adjectives
A useful first brief makes the scientific opportunity understandable without claiming more than the evidence shows. Keep confidential details out of the initial message unless your team has agreed how to share them.
- Opportunity: What problem is the programme intended to address, and why is the approach differentiated?
- Evidence available: What has actually been observed, under what conditions, and where are the limitations?
- Company status: Is this an academic discovery, a prospective spinout, an existing company or an asset available for licensing?
- People and assets: Who owns the work, which rights are established, and which questions require your advisers?
- Next milestone: What decision will the proposed work enable? Identify assumptions, dependencies and who will review the plan.
- Working model: Do you want capital, company formation, laboratory access, operating leadership or a combination?
Do not turn this into a checklist of experiments that every company must run. The scientific and regulatory plan belongs with the appropriate specialists. The founder's organizational job is to connect that plan, its evidence and its funding assumptions.
A worked shortlist for an academic spinout
Fictional example: A European academic team has an early therapeutic discovery, access to supporting data and discussions with its technology-transfer office. There is no established company, completed licence or assumed clinical result.
The team first compares company-creation routes, such as AdBio, Versant's European discovery-engine model and Sofinnova Partners' Capital strategy. Curie.Bio is another conversation to evaluate against its published worldwide scope and hands-on working model. These are candidates for investigation, not predictions of investor interest.
Biovance's evidence and asset requirements create a separate readiness question. If the team cannot yet explain the appropriate models or asset position, it should resolve that uncertainty before calling itself ready for that investor. Epidarex's US/UK focus is a geographic filter; a project elsewhere should not assume that a European label makes it eligible.
For each plausible route, the first ask is focused: does this scientific and company-formation stage fit your model, and what non-confidential material would be useful? The team can then prepare the relevant evidence rather than broadcasting a long deck to every healthcare fund.
Why the biggest biotech investor may not be the right first call
A large fund can invest at a later stage, buy public shares or operate several distinct strategies. Its size does not establish willingness to form a company or evaluate your present evidence. A smaller shortlist organized around stage, scientific focus and working model is more useful than a league table of capital raised.
Keep the company-creation conversation separate from the financing conversation until the firm confirms they are the same route. Ask who evaluates the science, what the process involves and which milestone would make the opportunity appropriate. Use the investment-committee guide to understand decision steps without assuming every firm uses an identical process.
Build a preclinical investor shortlist
Complete one card per investor and route. Mark unknowns explicitly, attach the official evidence and give the next question an owner. This keeps scientific readiness separate from fundraising activity.
PRECLINICAL INVESTOR FIT CARD
Company or project / country / scientific field:
Status: discovery / prospective spinout / existing company
Evidence available / limitations / source date:
Asset and IP position / adviser questions:
Next milestone / assumptions / dependencies:
Scientific and development-plan reviewer:
Funding purpose / cost assumptions / runway:
Need: capital / co-building / lab access / operating support
Investor / strategy / official URL / checked date:
Preclinical entry point and evidence threshold:
Geography / working-model fit / unknowns:
Public approach route / relationship context:
Reason to include or exclude:
Next question / owner / due date:Ask Aurora, Claude or Codex to review your shortlist
Supply your facts and the official sources. Review the result before acting; this is a research aid, not automatic outreach.
Review my preclinical biotech investor shortlist using only the company facts and official URLs I supply.
Separate company creation from investment in an existing company and preclinical milestones from clinical-stage strategies.
For each provider, return scientific-thesis fit, published entry stage, geography, operating model, approach route and unanswered questions.
Do not infer eligibility from office location, an old investment or fund size. Do not invent investor interest or available capital.
Organize the evidence gaps for review by our scientific, legal and regulatory advisers; do not prescribe experiments or give medical, legal or investment advice.
Draft a short non-confidential approach note for human review. Do not send it.Keep the science, sources and next conversation connected
Use Finta to organize investor contacts, official source links, relationship context and follow-up. Aurora can help turn the research into a working shortlist and prepare the next questions while your team reviews the scientific claims. Connect the process with the comprehensive seed fundraising guide and round-size planning worksheet.
Methodology and research date
Finta Editorial Team reviewed official investment strategies, company-building models, founder materials and contact routes on November 12, 2026. The list counts each firm or connected strategy family once. It excludes fund allocators, non-investing labs and firms without sufficient current entry-point evidence. Forbion and its described BGV seed relationship appear as one comparison, not duplicate provider names.
Published company creation establishes an early entry model, not an open offer to fund any external company. Geographic or operating restrictions not stated publicly remain unconfirmed. A public contact is not a promise of review or a meeting. An old programme call is not treated as currently open. This is general research, not investment, clinical, medical, regulatory or legal advice.